Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
TAO (troleandomycin) is an oral macrolide antibiotic suspension developed by Pfizer. The mechanism of action and approved indications are not currently specified in available data. This small-molecule antibiotic targets bacterial infections through standard macrolide pathways.
Pre-launch stage indicates emerging team-building phase with focus on regulatory completion, launch planning, and commercialization strategy preparation.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
ROTAO 1 - Feasibility and Safety of the TAVIPILOT Tele-operated Robot During Transcatheter Aortic Valve Replacement (TAVR/TAVI)
MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
TAO Outpatient Trial for Anxiety and Depression
TruFreeze™ Airway Obstruction: TAO STUDY
Worked on TAO at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Zero linked jobs currently reflects pre-launch status; career opportunities will emerge significantly upon FDA approval and launch preparation acceleration. Joining now offers rare ground-floor opportunity to build a brand from regulatory completion through commercial launch.